Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Oncology|October 14, 2020
Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective StudyYuichi Koda, Kozo Kuribayashi, Hiroshi Doi, et al.
Neuroimage|July 28, 2009
A new graphic plot analysis for determination of neuroreceptor binding in positron emission tomography studiesHiroshi Ito, Takashi Yokoi, Yoko Ikoma, et al.
Case Reports in Oncology|September 8, 2017
Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung CancerYuki Nakatani, Aya Nakaya, Takayasu Kurata, et al.
International Immunology|August 16, 2008
Mycobacterium bovis Bacillus Calmette-Guérin suppresses inflammatory Th2 responses by inducing functional alteration of TSLP-activated dendritic cellsTakashi Yokoi, Ryuichi Amakawa, Tsutomu Tanijiri, et al.
Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|March 4, 2008
Three cases of polymyositis/dermatomyositis complicated by pneumomediastinumKeiko Shimamoto, Yoshio Ozaki, Hideki Amuro, et al.
Hellenic Journal of Nuclear Medicine|December 13, 2021
The utility of 68F-FDG PET/CT for evaluation of tumor response to immune checkpoint inhibitor therapy and prognosis prediction in patients with non-small-cell lung cancerKazuhiro Kitajima, Yusuke Kawanaka, Hisashi Komoto, et al.
Thoracic Cancer|May 13, 2022
A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01)Kazuhiro Asami, Masahiko Ando, Takashi Nishimura, et al.
Molecular and Clinical Oncology|November 29, 2017
Retrospective analysis of single-agent nab-paclitaxel in patients with platinum-resistant non-small cell lung cancerAya Nakaya, Takayasu Kurata, Takashi Yokoi, et al.
Internal Medicine (Tokyo, Japan)|February 5, 2019
A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102Takashi Yokoi, Seigo Minami, Takayuki Shiroyama, et al.
Cancers|April 3, 2021
Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CTKazuhiro Kitajima, Mitsunari Maruyama, Hiroyuki Yokoyama, et al.
Pageof 9